Diabetic nephropathy (DN) is a major healthcare challenge. It occurs in up to 50% of those
living with diabetes, is a major cause of end‐stage kidney disease (ESKD) that requires …

Diabetic nephropathy is a significant cause of chronic kidney disease and end-stage renal
failure globally. Much research has been conducted in both basic science and clinical …

Background There is much uncertainty regarding the relative effects of angiotensin-
converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) in …

Background Microalbuminuria and hypertension are risk factors for diabetic nephropathy.
Blockade of the renin–angiotensin system slows the progression to diabetic nephropathy in …

The hyperfiltration theory: A paradigm shift in nephrology. Experimental studies incriminate
glomerular hypertension in mediating progressive renal damage after any of a variety of …

Background Drugs that inhibit angiotensin-converting enzyme slow the progression of renal
insufficiency in patients with diabetic nephropathy. Whether these drugs have a similar …

Background The multicenter double-blind, randomized Bergamo Nephrologic Diabetes
Complications Trial (BENEDICT) was designed to assess whether angiotensin-converting …

Purpose: To examine the efficacy of ACE inhibitors for treatment of nondiabetic renal
disease. Data Sources: 11 randomized, controlled trials comparing the efficacy of …

Objective.—To review the scientific evidence concerning the safety and efficacy of various
antihypertensive therapies used as first-line agents and evaluated in terms of major disease …

Objectives: To critically analyze the literature linking microalbuminuria with total and
cardiovascular mortality and cardiovascular morbidity in non—insulin—dependent diabetes …